Immune System News and Research

RSS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

New WHO policy recommendation warns against use of blood tests for active TB

A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis.

25 Jul 2011

New details about how dendritic cells regulate fate of naive T cells

St. Jude Children's Research Hospital scientists show that the molecule serves as a bridge between the two arms of the immune system that provides a new mechanism guiding T cell differentiation.

25 Jul 2011

Report on versatility of nitric oxide in arming hosts against pathogens

A new target for nitric oxide has been revealed in studies of how it inhibits the growth of Salmonella. This bacterium is a common cause of food-poisoning.

25 Jul 2011

Researchers dissociate beneficial and detrimental impacts of maternal regulatory T cells

A normal but concerning consequence of pregnancy is the fact that pregnant women are more susceptible to infection. University of Minnesota Medical School researchers have identified the underlying mechanisms for this physiologic immune suppression that may lead to new therapies to help ward off infections during pregnancy.

22 Jul 2011

Effects of refusal and delay in childhood vaccination

Alison M. Buttenheim, PhD, MBA, assistant professor at Penn Nursing answers parents' questions about childhood vaccines. Dr. Buttenheim is a public health researcher and social demographer who studies parent behavior and child health.

22 Jul 2011

Contaminated nasal spray associated with rare bacterial outbreak

Infection control researchers investigating a rare bacterial outbreak of Burholderia cepacia complex (Bcc) identified contaminated nasal spray as the root cause of the infections, leading to a national recall of the product.

22 Jul 2011

Impaired immunological memory causes psoriasis, atopic eczema

Scientists from the Centre for Allergy and Environment in Munich (ZAUM), the Helmholtz Zentrum München and the Technische Universität München have reached a milestone in their specialist area with their discovery of the causes of atopic eczema and psoriasis.

22 Jul 2011

Skin dendritic cells promote distinct and opposing antigen-specific responses

A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Cell biologists identify infection mechanism of adenoviruses

Mucosal epithelia do not have any receptors on the outer membrane for the absorption of viruses like hepatitis C, herpes, the adenovirus or polio, and are thus well-protected against pathogenic germs. However, certain viruses, such as the human immunodeficiency virus HIV, still manage to enter the body via the mucous membrane.

21 Jul 2011

New vaccine formulation may help heroin addicts maintain abstinence

Scientists are reporting development and successful initial laboratory tests on the key ingredient for a much-needed vaccine to help individuals addicted to heroin abstain from the illicit drug. Their study appears in ACS' Journal of Medicinal Chemistry.

21 Jul 2011